Sanofi Buys Biotech Startup Tidal Therapeutics for Initial $160 Million
09 Abril 2021 - 1:31PM
Noticias Dow Jones
By Colin Kellaher
Sanofi SA on Friday said it has acquired Tidal Therapeutics, a
preclinical-stage biotech startup using a novel mRNA-based approach
for in-vivo reprogramming of immune cells, for an initial $160
million.
The Paris pharmaceutical giant said it could make up to an
additional $310 in milestone payments as part of the deal, which it
said expands its research capabilities in immuno-oncology and
inflammatory diseases.
Sanofi said Tidal, based in Cambridge, Mass., uses a technology
based on proprietary nanoparticles that deliver mRNA to reprogram
immune cells inside the body. Tidal's current preclinical programs
include in-vivo reprogramming of T-cells or other types of immune
cells for cancer indications.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 09, 2021 14:16 ET (18:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
